Optimizing mRNA Formulations In A Bottlenecked & Bifurcated Supply Chain

During our Bioprocess Online Live event, mRNA Update: Beyond Prophylactic Vaccines, we asked an audience of several hundred biopharma professionals what they found most challenging about mRNA therapeutic development. The runaway leading response was screening, developing, and optimizing formulations during preclinical development. Here, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address overcoming that challenge in the context of a fragmented supply chain and outsourced environment.